[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

RU2011133893A - MEDICINAL FORM OF SLOW-DELIVERY OF GLUCOSAMINE - Google Patents

MEDICINAL FORM OF SLOW-DELIVERY OF GLUCOSAMINE Download PDF

Info

Publication number
RU2011133893A
RU2011133893A RU2011133893/15A RU2011133893A RU2011133893A RU 2011133893 A RU2011133893 A RU 2011133893A RU 2011133893/15 A RU2011133893/15 A RU 2011133893/15A RU 2011133893 A RU2011133893 A RU 2011133893A RU 2011133893 A RU2011133893 A RU 2011133893A
Authority
RU
Russia
Prior art keywords
dosage form
sustained release
glucosamine
release dosage
form according
Prior art date
Application number
RU2011133893/15A
Other languages
Russian (ru)
Other versions
RU2521231C2 (en
Inventor
Пукхрадж Чханданмал Ботхра
Раджу Нсв
Рагхупатхи Кандарапу
Рао Марам Самбасива
Махеш Кумар Т
Р. Сринивасан
Original Assignee
Медрейх Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медрейх Лимитед filed Critical Медрейх Лимитед
Priority to RU2011133893/15A priority Critical patent/RU2521231C2/en
Publication of RU2011133893A publication Critical patent/RU2011133893A/en
Application granted granted Critical
Publication of RU2521231C2 publication Critical patent/RU2521231C2/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Лекарственная форма замедленного высвобождения глюкозамина и его солей, содержащая гидроксипропилметилцеллюлозу с молекулярным весом от 100000 до 200000 в качестве средства, замедляющего высвобождение, и один или более фармацевтически приемлемых наполнителей.2. Лекарственная форма замедленного высвобождения по п.1, где соли глюкозамина выбраны из гидрохлорида, сульфата, фосфата, хлорида калия, хлорида натрия и их смесей.3. Лекарственная форма замедленного высвобождения по п.1, где один или более фармацевтически приемлемых наполнителей выбраны из разбавителя, связующего, дезинтегратора, смазывающего вещества, вещества, способствующего скольжению, и их комбинаций.4. Лекарственная форма замедленного высвобождения по п.1, которая может быть приготовлена с помощью влажной грануляции, сухой грануляции или прямого прессования.1. A sustained release dosage form of glucosamine and its salts containing hydroxypropyl methylcellulose with a molecular weight of from 100,000 to 200,000 as a release inhibitor and one or more pharmaceutically acceptable excipients. The sustained release dosage form according to claim 1, wherein the glucosamine salts are selected from hydrochloride, sulfate, phosphate, potassium chloride, sodium chloride, and mixtures thereof. The sustained release dosage form according to claim 1, wherein the one or more pharmaceutically acceptable excipients is selected from a diluent, a binder, a disintegrant, a lubricant, a glidant, and combinations thereof. The sustained release dosage form according to claim 1, which can be prepared by wet granulation, dry granulation or direct compression.

Claims (4)

1. Лекарственная форма замедленного высвобождения глюкозамина и его солей, содержащая гидроксипропилметилцеллюлозу с молекулярным весом от 100000 до 200000 в качестве средства, замедляющего высвобождение, и один или более фармацевтически приемлемых наполнителей.1. A dosage form for the sustained release of glucosamine and its salts, containing hydroxypropyl methylcellulose with a molecular weight of from 100,000 to 200,000 as a release inhibitor and one or more pharmaceutically acceptable excipients. 2. Лекарственная форма замедленного высвобождения по п.1, где соли глюкозамина выбраны из гидрохлорида, сульфата, фосфата, хлорида калия, хлорида натрия и их смесей.2. The sustained release dosage form according to claim 1, wherein the glucosamine salts are selected from hydrochloride, sulfate, phosphate, potassium chloride, sodium chloride, and mixtures thereof. 3. Лекарственная форма замедленного высвобождения по п.1, где один или более фармацевтически приемлемых наполнителей выбраны из разбавителя, связующего, дезинтегратора, смазывающего вещества, вещества, способствующего скольжению, и их комбинаций.3. The sustained release dosage form according to claim 1, wherein the one or more pharmaceutically acceptable excipients is selected from a diluent, a binder, a disintegrant, a lubricant, a glidant, and combinations thereof. 4. Лекарственная форма замедленного высвобождения по п.1, которая может быть приготовлена с помощью влажной грануляции, сухой грануляции или прямого прессования. 4. The sustained release dosage form according to claim 1, which can be prepared by wet granulation, dry granulation or direct compression.
RU2011133893/15A 2011-08-12 2011-08-12 Glucosamine prolonged release dosage form RU2521231C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2011133893/15A RU2521231C2 (en) 2011-08-12 2011-08-12 Glucosamine prolonged release dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2011133893/15A RU2521231C2 (en) 2011-08-12 2011-08-12 Glucosamine prolonged release dosage form

Publications (2)

Publication Number Publication Date
RU2011133893A true RU2011133893A (en) 2013-02-20
RU2521231C2 RU2521231C2 (en) 2014-06-27

Family

ID=49119811

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011133893/15A RU2521231C2 (en) 2011-08-12 2011-08-12 Glucosamine prolonged release dosage form

Country Status (1)

Country Link
RU (1) RU2521231C2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0612802A2 (en) * 2005-07-07 2010-11-30 Farnam Co Inc sustained release pharmaceutical compositions for extremely water soluble drugs
KR100840794B1 (en) * 2007-04-20 2008-06-23 주식회사 한미양행 Composition for high glucosamine content tablets and preparation method for the glucosamine tablets

Also Published As

Publication number Publication date
RU2521231C2 (en) 2014-06-27

Similar Documents

Publication Publication Date Title
RS54873B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
RS54207B1 (en) Condensed imidazolylimidazoles as antiviral compounds
EA201490419A1 (en) COMPOUNDS FOR THE TREATMENT AND PREVENTION OF RESPIRATORY SYNCIAL VIRAL DISEASE
EA201291282A1 (en) NITROGEN-CONTAINING HETEROARRYL COMPOUNDS
RS54386B1 (en) Antiviral compounds
EA201790661A2 (en) HEPATITIS C VIRUS INHIBITORS
RS54123B1 (en) Therapeutic combination comprising dolutegravir, abacavir and lamivudine
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
EA201490228A1 (en) NEW DERIVATIVES OF TRIFTOROMETHYLOROXIAZOLE AND THEIR APPLICATION FOR THE TREATMENT OF DISEASE
MX2016006336A (en) Pyrazolopyrimidine compounds.
EA201592255A1 (en) DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
UA109421C2 (en) PHARMACEUTICAL COMPOSITION CONTAINING SIGMA-RECEPTOR LIGANDS
EA201390917A1 (en) DIGETEROARYLIC CONNECTIONS AS VPS34 INHIBITORS
RU2014149181A (en) PYRAZOLE DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES
EA201300862A1 (en) INHIBITION OF IL17 AND IFN-GAMMA FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION
PE20161072A1 (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN
EA201490471A1 (en) PYRIDAZINOUS COMPOUNDS AND THEIR APPLICATION AS DAAO INHIBITORS
EA201190320A1 (en) HETEROCYCLIC SULPHONAMIDES, THEIR APPLICATIONS AND PHARMACEUTICAL COMPOSITIONS
EA201590475A1 (en) TETRACYCLINE CONNECTIONS
EA201591499A1 (en) SUBSTITUTED BISPHENYLBUTANE DERIVATIVES OF PHOSPHONE ACID AS NEP INHIBITORS (NEUTRAL ENDOPEPTIDASE)
EA201300034A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING IMATINIB OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, AND WAYS TO OBTAIN THEM
RS53152B (en) Novel antibacterial agents for the treatment of gram positive infections
EA201370149A1 (en) ANTAGONISTS RECEPTOR
EA201692298A1 (en) DERIVATIVES OF CARBOXAMIDES
EA201591177A1 (en) TRICYCLIC COMPOUNDS TO INHIBIT CFTR CHANNEL

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170813